Tesofensine: the striking weight-loss number with a big asterisk

Tesofensine has one of the most eye-catching numbers in obesity pharmacology — and one of the biggest asterisks. A single Phase II trial reported weight loss roughly double what the first generation of approved obesity drugs achieved, which is why it keeps resurfacing in “next big thing” coverage. But the evidence behind that number is thinner and more complicated than the headline suggests, and honesty about both halves is the point of this monograph.

What it is (and what it isn’t)

First, a clarification that matters: tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor — it blocks the presynaptic reuptake of noradrenaline, dopamine and serotonin, raising the levels of all three in the brain.^[1] That mechanism puts it closer to a stimulant/antidepressant class than to the peptide therapeutics elsewhere on this site. It was originally developed (as NS2330) for Alzheimer’s and Parkinson’s disease; weight loss showed up as a side effect in those neurodegeneration programs, and the drug was repurposed toward obesity.^[3]

The headline trial: TIPO-1

The number everyone cites comes from TIPO-1, a Phase II randomized, double-blind, placebo-controlled trial in 203 obese adults across five Danish centres, run over 24 weeks on top of an energy-restricted diet.^[1] The weight loss was dose-dependent and, at the higher doses, large:

At the 0.5 mg dose — the one usually proposed for development — mean weight loss was 9.2% versus 2.0% on diet and placebo; the 1.0 mg dose reached 10.6% but with more side effects.^[1] On its face, that is a very strong Phase II signal. The trouble is what came after.

What happened next: no confirmed Phase III

Despite the dramatic Phase II number, tesofensine never produced a published, completed Phase III trial confirming its weight-loss efficacy as a standalone obesity drug. The most recent randomized human data is for Tesomet, a combination of tesofensine with the beta-blocker metoprolol, tested in a small trial (n=21) in the niche condition of hypothalamic obesity — where it produced about 6.3% additional weight loss over 24 weeks.^[4] The metoprolol was added specifically to blunt tesofensine’s cardiovascular effects, which points to the safety issue below. Recent 2024–25 tesofensine research exists, but it is in rodents, not people — not human obesity evidence.

The safety signal: it’s a stimulant

Tesofensine behaves like the monoamine-raising drug it is. In TIPO-1 the most common adverse effects were dry mouth, nausea, constipation, hard stools, diarrhoea and insomnia, and while blood pressure did not rise significantly at the lower doses, heart rate increased by 7.4 beats per minute at the 0.5 mg dose.^[1] A raised heart rate is exactly the kind of cardiovascular signal that has sunk other centrally-acting appetite drugs, and it is why the later Tesomet program paired the drug with a beta-blocker. This is not a benign supplement-style compound.

Where it sits versus the approved options

It is tempting to line tesofensine’s 9.2% up against the GLP-1 drugs, but that is not a fair comparison: semaglutide and tirzepatide have multiple large Phase III trials and FDA approval, while tesofensine has one flagged Phase II trial and no approval. If you want a molecule with a similar weight-loss ambition but a real outcome record, the honest place to look is the approved incretins — compare them in our GLP-1 comparison tool and our roundup of peptides marketed for weight loss. For another metabolic compound running almost entirely on preclinical promise, see 5-Amino-1MQ.

The honest bottom line

Tesofensine is a genuinely interesting drug with a genuinely unsettled record. Its triple-monoamine mechanism produced a striking Phase II weight-loss result — but that result carries a journal Expression of Concern, was never confirmed in a completed Phase III, and comes with a stimulant-type cardiovascular profile.^[1][2] It is investigational, unapproved, and a long way from the evidence base of the drugs people can actually be prescribed. Treat the 9.2% as a promising but flagged signal, not a proven outcome — and treat anyone selling tesofensine today as operating well ahead of the science.